News Oculis Holding AG

Equities

OCS

CH1242303498

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
12.85 ^USD	-1.68%		+6.91%	+14.43%

Apr. 24	H.C. Wainwright Adjusts Price Target on Oculis Holding to $28 From $29, Keeps Buy Rating	MT
Apr. 24	Oculis Holding AG(NasdaqGM:OCS) added to OMX Nordic All-Share Index	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oculis Publishes Invitation to the Annual General Meeting	Apr. 29	AQ
H.C. Wainwright Adjusts Price Target on Oculis Holding to $28 From $29, Keeps Buy Rating	Apr. 24	MT
Oculis Holding AG(NasdaqGM:OCS) added to OMX Nordic All-Share Index	Apr. 23	CI
Oculis Completes $59 Million Direct Offering of Shares	Apr. 22	MT
Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market	Apr. 22	GL
Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market	Apr. 11	AQ
Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development	Apr. 10	AQ
Oculis Holding AG Strengthens its Executive Leadership Team with the Appointment of Snehal Shah as President of Research & Development	Apr. 10	CI
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting	Apr. 08	AQ
Oculis Holding Ag Announces Positive Results from Phase 3 Optimize-1 Trial of Once Daily Ocs-01 for the Treatment of Inflammation and Pain Following Cataract Surgery	Apr. 08	CI
Oculis to Participate at Upcoming April Investor Conferences	Apr. 04	AQ
Oculis Holding Files $300 Million Mixed-Securities Shelf Registration	Apr. 01	MT
Baird Adjusts Price Target on Oculis to $35 From $64, Maintains Outperform Rating	Mar. 19	MT
Oculis Narrows Q4 Loss, Improves Cash Position -- Shares Fall	Mar. 18	MT
Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress	Mar. 18	AQ
Oculis Holding AG Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 18	CI
Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments	Feb. 28	AQ
Oculis Holding AG Announces Executive Appointments	Feb. 28	CI
Oculis to Present at Upcoming February Investor Conferences	Jan. 29	AQ
Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024	Jan. 22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Oculis Holding AG

Equities

OCS

CH1242303498

Summary

Filters